Philadelphia Trust Company’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.87M | Hold |
2,415
| – | – | 0.13% | 86 |
|
|
2025
Q4 | $1.86M | Hold |
2,415
| – | – | 0.13% | 87 |
|
|
2025
Q3 | $1.36M | Hold |
2,415
| – | – | 0.1% | 101 |
|
|
2025
Q2 | $1.27M | Hold |
2,415
| – | – | 0.1% | 105 |
|
|
2025
Q1 | $1.53M | Hold |
2,415
| – | – | 0.13% | 94 |
|
|
2024
Q4 | $1.72M | Hold |
2,415
| – | – | 0.13% | 92 |
|
|
2024
Q3 | $2.54M | Buy |
2,415
+1,250
| +107% | +$1.39M | 0.18% | 79 |
|
|
2024
Q2 | $1.22M | Sell |
1,165
-8
| -0.7% | -$7.75K | 0.1% | 102 |
|
|
2024
Q1 | $1.13M | Buy |
1,173
+15
| +1% | +$14.3K | 0.09% | 112 |
|
|
2023
Q4 | $1.02M | Hold |
1,158
| – | – | 0.1% | 116 |
|
|
2023
Q3 | $953K | Hold |
1,158
| – | – | 0.1% | 117 |
|
|
2023
Q2 | $832K | Hold |
1,158
| – | – | 0.08% | 126 |
|
|
2023
Q1 | $951K | Hold |
1,158
| – | – | 0.1% | 120 |
|
|
2022
Q4 | $835K | Sell |
1,158
-250
| -18% | -$184K | 0.09% | 125 |
|
|
2022
Q3 | $970K | Hold |
1,408
| – | – | 0.11% | 106 |
|
|
2022
Q2 | $832K | Sell |
1,408
-4,224
| -75% | -$2.75M | 0.09% | 118 |
|
|
2022
Q1 | $3.93M | Buy |
5,632
+4,232
| +302% | +$2.68M | 0.31% | 67 |
|
|
2021
Q4 | $884K | Hold |
1,400
| – | – | 0.06% | 134 |
|
|
2021
Q3 | $847K | Hold |
1,400
| – | – | 0.06% | 139 |
|
|
2021
Q2 | $782K | Hold |
1,400
| – | – | 0.05% | 153 |
|
|
2021
Q1 | $662K | Buy |
+1,400
| New | +$682K | 0.05% | 152 |
|
|
2020
Q3 | – | Sell |
-404
| Closed | -$252K | – | 200 |
|
|
2020
Q2 | $252K | Sell |
404
-96
| -19% | -$54.5K | 0.03% | 162 |
|
|
2020
Q1 | $244K | Sell |
500
-1,058
| -68% | -$436K | 0.03% | 150 |
|
|
2019
Q4 | $585K | Sell |
1,558
-93
| -6% | -$31.3K | 0.05% | 146 |
|
|
2019
Q3 | $458K | Hold |
1,651
| – | – | 0.04% | 162 |
|
|
2019
Q2 | $517K | Buy |
+1,651
| New | +$550K | 0.05% | 162 |
|
|
2018
Q4 | – | Sell |
-650
| Closed | -$263K | – | 194 |
|
|
2018
Q3 | $263K | Buy |
+650
| New | +$247K | 0.02% | 185 |
|
|
2017
Q4 | – | Sell |
-19,136
| Closed | -$8.56M | – | 229 |
|
|
2017
Q3 | $8.56M | Buy |
19,136
+17,056
| +820% | +$8.12M | 0.7% | 48 |
|
|
2017
Q2 | $1.02M | Sell |
2,080
-500
| -19% | -$219K | 0.09% | 120 |
|
|
2017
Q1 | $1M | Hold |
2,580
| – | – | 0.08% | 120 |
|
|
2016
Q4 | $947K | Hold |
2,580
| – | – | 0.08% | 129 |
|
|
2016
Q3 | $1.04M | Hold |
2,580
| – | – | 0.09% | 120 |
|
|
2016
Q2 | $901K | Hold |
2,580
| – | – | 0.08% | 123 |
|
|
2016
Q1 | $930K | Sell |
2,580
-625
| -20% | -$258K | 0.08% | 109 |
|
|
2015
Q4 | $1.75M | Hold |
3,205
| – | – | 0.15% | 82 |
|
|
2015
Q3 | $1.49M | Buy |
3,205
+1,075
| +50% | +$577K | 0.13% | 88 |
|
|
2015
Q2 | $4.17K | Sell |
2,130
-3,020
| -59% | -$1.47M | 0.02% | 168 |
|
|
2015
Q1 | $2.33M | Hold |
5,150
| – | – | 0.18% | 81 |
|
|
2014
Q4 | $2.11M | Hold |
5,150
| – | – | 0.17% | 73 |
|
|
2014
Q3 | $1.86M | Sell |
5,150
-1,975
| -28% | -$662K | 0.12% | 80 |
|
|
2014
Q2 | $2.01M | Buy |
7,125
+600
| +9% | +$178K | 0.13% | 78 |
|
|
2014
Q1 | $1.96M | Buy |
6,525
+5,525
| +553% | +$1.7M | 0.12% | 71 |
|
|
2013
Q4 | $275K | Hold |
1,000
| – | – | 0.02% | 175 |
|
|
2013
Q3 | $313K | Buy |
+1,000
| New | +$263K | 0.02% | 152 |
|
Other funds holding REGN
VCM
N
Philadelphia Trust Company's REGN Position: Q1 2026 in Review
Philadelphia Trust Company held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 2,415 shares worth $1.87M. The position accounts for 0.13% of the portfolio, ranked #86.
Philadelphia Trust Company first reported a position in REGN in Q3 2013 and has held it in 44 quarters since. The position peaked at $8.56M in Q3 2017. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Philadelphia Trust Company held 2,415 shares of Regeneron Pharmaceuticals worth $1.87M as of Q1 2026.
- Philadelphia Trust Company left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
- Regeneron Pharmaceuticals made up 0.13% of Philadelphia Trust Company's portfolio in Q1 2026, its #86 holding.
- Philadelphia Trust Company first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 44 quarters since.
- Philadelphia Trust Company's Regeneron Pharmaceuticals position peaked at $8.56M in Q3 2017.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Philadelphia Trust Company's 13F filing for Q1 2026, filed 13 May 2026.